Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.7% |
| 2 | Financials | 7.47% |
| 3 | Consumer Discretionary | 6.7% |
| 4 | Communication Services | 6.02% |
| 5 | Healthcare | 4.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3801
iShares iBonds Dec 2033 Term Corporate ETF
IBDY
$1.09B
| $497K | ﹤0.01% |
19,019
| – | – |
|
3802
Plumas Bancorp
PLBC
$439M
| $497K | ﹤0.01% |
11,116
+1,651
| +17% | +$70.8K |
|
3803
Titan Machinery
TITN
$431M
| $495K | ﹤0.01% |
32,914
+3,553
| +12% | +$57.2K |
|
|
ALMU
3804
Aeluma Inc
ALMU
$330M
| $494K | ﹤0.01% |
28,748
+14,841
| +107% | +$234K |
|
|
PAL
3805
Proficient Auto Logistics
PAL
$150M
| $492K | ﹤0.01% |
51,022
+15,464
| +43% | +$121K |
|
3806
Teleflex
TFX
$5.78B
| $492K | ﹤0.01% |
4,028
+708
| +21% | +$85.8K |
|
3807
Lyell Immunopharma
LYEL
$347M
| $491K | ﹤0.01% |
15,967
+14,775
| +1,240% | +$331K |
|
|
PPIH
3808
Perma-Pipe International
PPIH
$216M
| $491K | ﹤0.01% |
16,184
+14,505
| +864% | +$398K |
|
3809
CALL
Elevance Health
ELV
$86.6B
| $491K | ﹤0.01% |
1,400
| – | – |
|
3810
Coherus Oncology
CHRS
$181M
| $491K | ﹤0.01% |
345,573
+52,381
| +18% | +$76.3K |
|
3811
Occidental Petroleum Corp Warrants
OXY.WS
$34.4B
| $489K | ﹤0.01% |
25,403
-221
| -0.9% | -$4.39K |
|
|
DENN
3812
DELISTED
Denny's
DENN
| $489K | ﹤0.01% |
78,597
+7,656
| +11% | +$43.4K |
|
3813
CALL
Republic Services
RSG
$65.6B
| $487K | ﹤0.01% |
2,300
-100
| -4% | -$21.5K |
|
3814
Xperi
XPER
$321M
| $487K | ﹤0.01% |
83,178
+15,128
| +22% | +$94.9K |
|
3815
Simulations Plus
SLP
$371M
| $485K | ﹤0.01% |
26,631
+2,141
| +9% | +$37.6K |
|
3816
Puma Biotechnology
PBYI
$459M
| $485K | ﹤0.01% |
81,434
+1,553
| +2% | +$8.25K |
|
3817
Ascent Industries
ACNT
$133M
| $484K | ﹤0.01% |
29,881
+2,107
| +8% | +$29K |
|
|
VOXR
3818
Vox Royalty Corp
VOXR
$356M
| $484K | ﹤0.01% |
102,016
+38,225
| +60% | +$173K |
|
3819
Cabaletta Bio
CABA
$465M
| $483K | ﹤0.01% |
220,696
+217,613
| +7,058% | +$539K |
|
3820
American Vanguard Corp
AVD
$64M
| $482K | ﹤0.01% |
126,269
+4,391
| +4% | +$20.5K |
|
3821
CALL
Joby Aviation
JOBY
$7.87B
| $482K | ﹤0.01% |
36,500
-13,500
| -27% | -$207K |
|
3822
Electromed
ELMD
$352M
| $479K | ﹤0.01% |
16,464
+2,147
| +15% | +$56.3K |
|
3823
American Coastal Insurance
ACIC
$465M
| $479K | ﹤0.01% |
37,920
+3,547
| +10% | +$42.8K |
|
3824
Celanese
CE
$4.75B
| $478K | ﹤0.01% |
11,316
-6,609
| -37% | -$270K |
|
3825
loanDepot
LDI
$298M
| $478K | ﹤0.01% |
230,946
+105,175
| +84% | +$292K |
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $49.1B in Q4 2025, closing 641 positions and reducing 1,715 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.